Get the Stockscreener App
0.2759
9.60%
-0.0293
After Hours:
.29
0.0141
+5.11%
Azitra Inc stock is traded at $0.2759, with a volume of 1.04M.
It is down -9.60% in the last 24 hours and down -19.96% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.3052
Open:
$0.3
24h Volume:
1.04M
Relative Volume:
0.41
Market Cap:
$2.96M
Revenue:
$1.27M
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.0123
EPS:
-22.4496
Net Cash Flow:
$-10.46M
1W Performance:
-3.02%
1M Performance:
-19.96%
6M Performance:
+19.23%
1Y Performance:
-52.02%
1-Day Range:
$0.273
$0.30
1-Week Range:
$0.2728
$0.32
52-Week Range:
$0.1305
$1.40
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.2759 | 3.28M | 1.27M | -11.28M | -10.46M | -22.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.67 | 116.86B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
758.91 | 80.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
810.51 | 49.26B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
369.96 | 49.00B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.06 | 36.96B | 4.98B | 69.59M | 525.67M | 0.5197 |
Azitra Inc Stock (AZTR) Latest News
IPO Launch: Is Azitra Inc stock supported by innovation pipelineJuly 2025 Levels & Fast Moving Trade Plans - moha.gov.vn
Rate Hike: How currency fluctuations impact UMBFP stock2025 Market WrapUp & Weekly Setup with ROI Potential - moha.gov.vn
What insider trading reveals about Azitra Inc. stock2025 Short Interest & Weekly High Return Stock Opportunities - Улправда
Why Azitra Inc. stock remains a top recommendationWeekly Gains Report & AI Enhanced Trading Alerts - Улправда
Can Azitra Inc. stock attract ESG capital inflowsWeekly Trend Recap & Consistent Income Trade Ideas - Улправда
How Azitra Inc. stock benefits from tech adoptionJuly 2025 Volume & Short-Term Trading Alerts - Улправда
What margin trends mean for Azitra Inc. stock2025 Biggest Moves & Daily Profit Maximizing Tips - ulpravda.ru
What risks investors should watch in Azitra Inc. stockGap Down & Weekly Sector Rotation Insights - Улправда
Will Azitra Inc. stock outperform Nasdaq indexJuly 2025 Review & Risk Managed Trade Strategies - Улправда
Why Azitra Inc. stock could rally in 2025July 2025 Catalysts & Weekly Stock Performance Updates - Улправда
Will Azitra Inc stock deliver shareholder valueJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - moha.gov.vn
US Market Wrap: What risks investors should watch in Azitra Inc. stock - ulpravda.ru
Will Azitra Inc. stock attract ESG investorsSupport and Resistance Levels & Superior Wealth Strategies - Улправда
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference - Barchart.com
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference | AZTR Stock News - Longbridge
Growth Recap: Can Azitra Inc stock attract ESG capital inflowsLong Setup & Daily Price Action Insights - moha.gov.vn
AZTR SEC FilingsAzitra Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Azitra says NYSE American approves compliance plan - MSN
[PRE 14A] Azitra, Inc. Preliminary Proxy Statement - Stock Titan
Azitra (AZTR) insider receives 23,724 stock options at $0.2968 - Stock Titan
Azitra (AZTR) CEO Francisco Salva granted 59,309 stock options - Stock Titan
[Form 4] Azitra, Inc. Insider Trading Activity - Stock Titan
Azitra (AZTR) CFO awarded 15,015 stock options vesting over 3 years - Stock Titan
Azitra (AZTR) director John R. Schroer receives 3,003 stock options grant - Stock Titan
Highs Report: Will Azitra Inc. stock see PE expansionJuly 2025 Analyst Calls & Risk Controlled Daily Trade Plans - Улправда
Why analysts upgrade Azitra Inc. stockQuarterly Growth Report & Technical Entry and Exit Tips - Улправда
Is Azitra Inc. stock a buy for dividend growth2025 Breakouts & Breakdowns & Weekly Return Optimization Alerts - Улправда
Is Azitra Inc stock positioned for secular growth2025 Price Momentum & Real-Time Volume Analysis - Улправда
Will Azitra Inc. stock see PE expansionWeekly Stock Report & Free Technical Pattern Based Buy Signals - Улправда
Azitra (AZTR) filing shows Alumni Capital 9.99% beneficial holding - Stock Titan
Azitra receives NYSE American approval of listing compliance plan - MSN
Bear Alert: How Azitra Inc. stock benefits from tech adoptionJuly 2025 Drop Watch & Risk Managed Investment Signals - Bölüm Sonu Canavarı
Aug Action: Will Azitra Inc. stock attract ESG investorsJuly 2025 Chart Watch & AI Optimized Trade Strategies - Улправда
Is Azitra Inc. stock positioned for digital transformationEarnings Beat & Consistent Return Investment Signals - Улправда
Why Azitra Inc stock is favored by hedge fundsWeekly Market Outlook & Community Trade Idea Sharing - Улправда
Aug Final Week: Will Azitra Inc. stock attract ESG investorsPortfolio Return Summary & Daily Oversold Bounce Ideas - Улправда
Azitra receives approval for NYSE American compliance plan By Investing.com - Investing.com India
Azitra receives approval for NYSE American compliance plan - Investing.com
Azitra Inc Compliance Plan Approved by NYSE American - TipRanks
Azitra (NYSE: AZTR) outlines NYSE American compliance plan after equity notice - Stock Titan
Azitra receives notice of acceptance of the listing standards compliance plan from NYSE American - marketscreener.com
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American - Nasdaq
Azitra (NYSE American: AZTR) details 51.8M-share resale and ELOC dilution - Stock Titan
Azitra files to sell 38.9M shares of common stock for holders - MSN
Azitra (NYSEAMERICAN:AZTR) Trading Down 4.7% – Here’s Why - Defense World
Azitra Inc (AZTR) -5.33% in After-hours: Declines Despite Recent Developments - Stocks Telegraph
Azitra (NYSE: AZTR) files S-1 for 51.8M resale shares under Alumni Capital deals - Stock Titan
Trade Report: Why analysts upgrade Azitra Inc stock2025 Top Gainers & Verified Short-Term Plans - moha.gov.vn
Azitra (AZTR) Price Target Decreased by 77.48% to 2.75 - Nasdaq
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR) - The Globe and Mail
How Azitra Inc stock reacts to weak economyWeekly Risk Report & Accurate Technical Buy Alerts - Newser
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.73%
2.37%
Cap:
|
Volume (24h):